The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.

Résumé : Mantle Cell Lymphoma (MCL) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MCL is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MCL therapies and about associated predictors remains poor. The REFRACT-LYMA Cohort, a multicenter prospective cohort of patients with MCL, is set up to address this limitation. We here describe the study background, design and methods used for this cohort.
Abstract : Background: Mantle Cell Lymphoma (MCL) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MCL is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MCL therapies and about associated predictors remains poor. The REFRACT-LYMA Cohort, a multicenter prospective cohort of patients with MCL, is set up to address this limitation. We here describe the study background, design and methods used for this cohort. Methods/Design: The REFRACT-LYMA Cohort Study aims at including all patients (>18 years old) who are diagnosed with MCL in any stage of the disease and treated in specialized oncology centers in three public hospitals in Northwestern France. Any such patient providing a signed informed consent is included. All subjects are followed up indefinitely, until refusal to participate in the study, emigration or death. The REFRACT-LYMA follow-up is continuous and collects data on socioeconomic status, medical status, MCL therapies and associated events (resistance, side effects). Participants also complete standardized quality of life (QOL) questionnaires. In addition, participants are asked to donate blood samples that will support ex vivo analysis of expression and functional assays required to uncover predictive biomarkers and companion diagnostics. If diagnostic biopsies are performed during the course of the disease, extracted biological samples are kept in a dedicated biobank.
Type de document :
Article dans une revue
BMC Cancer, BioMed Central, 2016, 16 (1), pp.802. 〈10.1186/s12885-016-2844-6〉
Liste complète des métadonnées

Littérature citée [32 références]  Voir  Masquer  Télécharger

https://hal.archives-ouvertes.fr/hal-01524145
Contributeur : Laurence Naiglin <>
Soumis le : vendredi 9 mars 2018 - 13:41:26
Dernière modification le : vendredi 9 novembre 2018 - 01:03:51

Fichier

s12885-016-2844-6.pdf
Publication financée par une institution

Identifiants

Citation

Matthieu Hanf, David Chiron, Sophie De Visme, Cyrille Touzeau, Hervé Maisonneuve, et al.. The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.. BMC Cancer, BioMed Central, 2016, 16 (1), pp.802. 〈10.1186/s12885-016-2844-6〉. 〈hal-01524145〉

Partager

Métriques

Consultations de la notice

181

Téléchargements de fichiers

31